罗格列酮治疗2型糖尿病疗效观察被引量：1

Efficacy of rosiglitazone on treating Type 2 diabetes

导出

摘要目的:探讨罗格列酮治疗2型糖尿病的临床疗效和安全性。方法:2型糖尿病患者90例,按治疗前用药情况分为罗格列酮治疗组(R组),合用磺脲治疗组(B组),合用二甲双胍治疗组(A组),每组30例。R组先行饮食及运动治疗,A组及B组保持原药物剂量不变,然后3组均给予罗格列酮4mg,每d1次,空腹口服,共51周。治疗前后抽取患者静脉血,葡萄糖氧化酶法测空腹血糖(FBG)及餐后2h血糖(P2hBG);测糖化血红蛋白;放免法测空腹胰岛素(FINS);计算胰岛素敏感性指数(A)和胰岛素抵抗指数(R)。结果:治疗后3组患者FBG、P2hBG、糖化血红蛋白、FINS水平及R值均较治疗前下降,A升高。上述各指标治疗前后的变化3组间比较差异无统计学意义(P>0.05)。3组均未发生严重不良反应。结论:罗格列酮可单用或与二甲双胍、磺脲类合用,治疗2型糖尿病安全、有效。 Aim ： To observe the efficacy of rosiglitazone on treating Type 2 diabetes. Methods： A total of 90 patients with Type 2 diabetes were allocated into 3 groups,30 in each group. Group R （which were treated with rosiglitazone） accepted diet control and had physical exercises,group A treated with sulfonylurea and group B treated with metformin before maintained the former administration. Then the 3 groups were all administrated rosiglitazone at a dose of 4 mg, 1 time per day for 51 weeks. Fasting blood glucose（FBG） , P2hBG, saccharification hemoglobin（HbAli） ,and fasting insuline（FINS） were determined before and after therapy, and resistance index（R） and sensitivity index（A） to insulin were calculated. Results ： FBG, P2hBG, HbAli, FINS, and R were decreased, and A was increased significantly in 3 groups of the pationts after treating with rosiglitazone. Conclusion： Rosiglitazone,or combined with sulfonylurea or metformin,is effective and safe in treatment of Type 2 diabetes.

作者郝齐志

机构地区商丘市第一人民医院内分泌科

出处《郑州大学学报（医学版）》 CAS 北大核心 2005年第5期898-899,共2页 Journal of Zhengzhou University(Medical Sciences)

关键词罗格列酮 2型糖尿病疗效 rosiglitazone Type 2 diabetes efficacy

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献2

1李全民,张素华,任伟,倪银星,吴静.罗格列酮对胰岛素抵抗大鼠胰岛素增敏作用及对解偶联蛋白基因表达的影响[J].郑州大学学报（医学版）,2003,38(3):374-377. 被引量：7
2Glaser V. New criteria for diagnosis, screening and classification. Patient Care, 1998,2 ( 2 ): 12.

二级参考文献14

1Tafuri SR. Troglitazone enhances differentiation, basal glucose uptake, and Glut I protein levels in 3T3-L1 adipocytes. Endocrinology, 1996, 137:4 705.
2Sidell RJ, Cole MA, Draper NJ, et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes, 2002, 51 (4) : 1 110.
3Schrauwen P, Xia J, Bogardus C, et al. Skeletal muscle uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians. Diabetes, 1999, 48( 1 ) : 146.
4Tsakiridis T, Vranie M, Klip A. Phosphatidylinositol3-kinase and the actin network are not required for the stimulation of glucose transport caused by mitochondrial uncoupling:comparison with insulin action. Biochem J, 1995, 309(Pt 1):1.
5Storlien LH, James DE, Burleigh KM, et al. Fat feeding causes widespread in vivo insulin resistance,decreased energy expenditure and obesity in the rat. Am J Physiol, 1986,251(5 Pt 1):E576.
6Cabrero A, Liaverias G, Roglans N, et al. Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. Bichem Biophys Ras Commun, 1999, 260(2) :547.
7Schrauwen P, Wagenmakers A J, van-Marken-Lichtenbelt WD, et al. Increase in fat oxidation on a high-fat diet is accompanied by an increase in triglyceride-derived fatty acid oxidation. Diabetes, 2000, 49 (4) : 640.
8Ye JM, Doyle PL, Iglesias MA, et al. Peroxisome proliferator-activated receptor( PPAR)-alpha activiation lowers muscle lipids and improves insulin sensitivity in high fat-fat rat:comparision with PPAR-gamma activition. Diabetes, 2001,50(2) : 411.
9Cabrero A, Alegret R, Sanchez RM, et al. Bezafibrate reduces mRNA levels of Adipocyte Markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes,2001, 50(8):1 883.
10Chaput E, Saladin R, Silvestre M, et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun, 2000,271(2) : 445.